Vignesh Gunasekaran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vignesh Gunasekaran has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Soowan Woo
SUNY Downstate Health Sciences University, New York, United States
5 shared publications Parvesh Mohan Garg
Wake Forest School of Medicine, North Carolina, United States
3 shared publicationsAndrew Michael South
Department of Pediatrics/Section of Nephrology, Wake Forest University School of Medicine, Winston Salem, North Carolina, United States
2 shared publicationsAvinash K. Shetty
Atrium Health Wake Forest Baptist, Wake Forest School of Medicine, North Carolina, United States
2 shared publicationsDavid Askenazi
Department of Pediatrics/Division of Nephrology, University of Alabama at Birmingham, Birmingham, Alabama, United States
2 shared publicationsJeffrey Shenberger
Department of Pediatrics/Neonatology, Connecticut Children's, Hartford, Connecticut, United States
2 shared publications
Latest Publications
- 19 November 2026
- Published by Georg Thieme Verlag KG in American Journal of Perinatology
Emerging Insights into the Dysregulated Monocyte-Macrophage Axis in Necrotizing Enterocolitis
Objective: To synthesize correlative human, descriptive transcriptomic, and murine evidence on the role of monocyte-macrophage dysregulation in the pathogenesis of necrotizing enterocolitis (NEC), using a structured evidence-tier framework not previously applied to this literature. Study Design: Narrative synthesis and critical appraisal of the peer-reviewed literature on monocyte and macrophage biology in NEC, organized by evidentiary tier: correlative human biomarker and tissue data, descriptive single-cell transcriptomic profiling, and interventional murine studies (macrophage depletion and ferroptosis inhibition). Results: The preterm intestinal macrophage shows paradoxically elevated TLR4 expression and an immature, fetal-derived phenotype lacking tolerogenic programming. Peripheral monocytopenia, particularly serial percentage decline in absolute monocyte count, correlates with NEC onset and severity across three independent cohorts and offers a zero-cost clinical biomarker. Single-cell transcriptomics identifies four functionally distinct macrophage subpopulations in NEC tissue, dominated by an oxidative-stress-related, injury-amplifying subtype. Murine studies provide supportive evidence for a mechanistic contribution: selective macrophage depletion attenuates transfusion-associated NEC-like injury, and pharmacologic inhibition of macrophage ferroptosis limits epithelial damage. Separately, epithelium-derived HMGB1 activates microglial TLR4, a resident macrophage-lineage population, linking intestinal injury to the neurodevelopmental impairment observed in survivors. Conclusion: Dysregulation of monocyte-macrophage pathways plays a significant role in the pathogenesis of NEC, supported by convergent correlative, descriptive, and interventional evidence. These findings reframe NEC as a disease of myeloid imbalance and identify macrophage-targeted strategies, including TLR4 modulation and ferroptosis-targeted therapy, as rational directions for future prevention and treatment.
- 19 November 2026
- Published by Georg Thieme Verlag KG in American Journal of Perinatology
Emerging Insights into the Dysregulated Monocyte-Macrophage Axis in Necrotizing Enterocolitis
Objective: To synthesize correlative human, descriptive transcriptomic, and murine evidence on the role of monocyte-macrophage dysregulation in the pathogenesis of necrotizing enterocolitis (NEC), using a structured evidence-tier framework not previously applied to this literature. Study Design: Narrative synthesis and critical appraisal of the peer-reviewed literature on monocyte and macrophage biology in NEC, organized by evidentiary tier: correlative human biomarker and tissue data, descriptive single-cell transcriptomic profiling, and interventional murine studies (macrophage depletion and ferroptosis inhibition). Results: The preterm intestinal macrophage shows paradoxically elevated TLR4 expression and an immature, fetal-derived phenotype lacking tolerogenic programming. Peripheral monocytopenia, particularly serial percentage decline in absolute monocyte count, correlates with NEC onset and severity across three independent cohorts and offers a zero-cost clinical biomarker. Single-cell transcriptomics identifies four functionally distinct macrophage subpopulations in NEC tissue, dominated by an oxidative-stress-related, injury-amplifying subtype. Murine studies provide supportive evidence for a mechanistic contribution: selective macrophage depletion attenuates transfusion-associated NEC-like injury, and pharmacologic inhibition of macrophage ferroptosis limits epithelial damage. Separately, epithelium-derived HMGB1 activates microglial TLR4, a resident macrophage-lineage population, linking intestinal injury to the neurodevelopmental impairment observed in survivors. Conclusion: Dysregulation of monocyte-macrophage pathways plays a significant role in the pathogenesis of NEC, supported by convergent correlative, descriptive, and interventional evidence. These findings reframe NEC as a disease of myeloid imbalance and identify macrophage-targeted strategies, including TLR4 modulation and ferroptosis-targeted therapy, as rational directions for future prevention and treatment.
- Open Access
- 2 November 2026
- Published by European Open Science in European Journal of Clinical Medicine
- Vol. 7  (6) , 16-21
NICU Admissions Among Late Preterm Infants at a Rural Community Birthing Center: A Retrospective Descriptive Study
Background: Late preterm infants (LPIs), born at 350/7–366/7 weeks gestation, carry a two to threefold elevated risk of neonatal morbidity compared with term newborns. In 2023, Berkeley Medical Center (BMC), a rural community hospital in West Virginia, revised its NICU admission threshold from less than 360/7 to less than 350/7 weeks, resulting in increased secondary transfers of LPIs from the Mother Baby Unit (MBU) to the NICU.Methods: A retrospective descriptive study was conducted using electronic medical records of all LPIs born at BMC from January 2023 to June 2024 (N = 157). Infants were stratified into three groups: direct NICU admission (Group 1), MBU admission with subsequent NICU transfer after ≥30 minutes of life (Group 2), and MBU admission without NICU transfer (Group 3). Descriptive statistics, chi-square tests, and one-way ANOVA with post-hoc comparisons were used.Results: Of 157 LPIs, 47 (30.0%) were admitted directly to the NICU, 47 (30.0%) were transferred from the MBU to the NICU, and 63 (40.1%) remained in the MBU throughout, yielding a total NICU admission rate of 59.9%. Group 1 had significantly lower mean gestational age (35.82 vs. 36.28 weeks; p < 0.001) and 1-minute Apgar scores (5.98 vs. 7.84; p < 0.001) compared with Group 3. Delivery room PPV (25.5% vs. 0%; p < 0.001) and CPAP use (48.9% vs. 1.6%; p < 0.001) were significantly higher in Group 1. Respiratory distress was the leading reason for direct NICU admission (46.8%) and MBU-to-NICU transfer (17.0%). NICU-admitted infants had significantly higher peak bilirubin levels (11.4–11.5 vs. 9.7 mg/dL; p = 0.001) and longer hospital stays (5.5–5.8 vs. 2.6 days; p < 0.001). Antenatal corticosteroid completeness (p = 0.006) and intrapartum antibiotic prophylaxis adequacy (p = 0.002) also differed significantly across groups.Conclusion: At this rural community birthing center, 60% of LPIs required NICU-level care following a threshold guideline revision. The equal burden of direct and secondary NICU admissions identifies a critical gap in MBU-level risk stratification. These findings support development of standardized LPI care protocols, enhanced delivery room readiness, and quality improvement initiatives to reduce preventable NICU admissions.
- 2 November 2026
- Published by European Open Science in European Journal of Clinical Medicine
- Vol. 7  (6) , 16-21
Open AccessNICU Admissions Among Late Preterm Infants at a Rural Community Birthing Center: A Retrospective Descriptive Study
Background: Late preterm infants (LPIs), born at 350/7–366/7 weeks gestation, carry a two to threefold elevated risk of neonatal morbidity compared with term newborns. In 2023, Berkeley Medical Center (BMC), a rural community hospital in West Virginia, revised its NICU admission threshold from less than 360/7 to less than 350/7 weeks, resulting in increased secondary transfers of LPIs from the Mother Baby Unit (MBU) to the NICU.Methods: A retrospective descriptive study was conducted using electronic medical records of all LPIs born at BMC from January 2023 to June 2024 (N = 157). Infants were stratified into three groups: direct NICU admission (Group 1), MBU admission with subsequent NICU transfer after ≥30 minutes of life (Group 2), and MBU admission without NICU transfer (Group 3). Descriptive statistics, chi-square tests, and one-way ANOVA with post-hoc comparisons were used.Results: Of 157 LPIs, 47 (30.0%) were admitted directly to the NICU, 47 (30.0%) were transferred from the MBU to the NICU, and 63 (40.1%) remained in the MBU throughout, yielding a total NICU admission rate of 59.9%. Group 1 had significantly lower mean gestational age (35.82 vs. 36.28 weeks; p < 0.001) and 1-minute Apgar scores (5.98 vs. 7.84; p < 0.001) compared with Group 3. Delivery room PPV (25.5% vs. 0%; p < 0.001) and CPAP use (48.9% vs. 1.6%; p < 0.001) were significantly higher in Group 1. Respiratory distress was the leading reason for direct NICU admission (46.8%) and MBU-to-NICU transfer (17.0%). NICU-admitted infants had significantly higher peak bilirubin levels (11.4–11.5 vs. 9.7 mg/dL; p = 0.001) and longer hospital stays (5.5–5.8 vs. 2.6 days; p < 0.001). Antenatal corticosteroid completeness (p = 0.006) and intrapartum antibiotic prophylaxis adequacy (p = 0.002) also differed significantly across groups.Conclusion: At this rural community birthing center, 60% of LPIs required NICU-level care following a threshold guideline revision. The equal burden of direct and secondary NICU admissions identifies a critical gap in MBU-level risk stratification. These findings support development of standardized LPI care protocols, enhanced delivery room readiness, and quality improvement initiatives to reduce preventable NICU admissions.
- 20 July 2026
- Published by Georg Thieme Verlag KG in American Journal of Perinatology
COVID-19 and Global Perinatal Health: Lessons Learned on Maternal-Neonatal Outcomes, Infant Feeding Practices, and Health Care Economics across Income Settings
The coronavirus disease 2019 (COVID-19) pandemic fundamentally disrupted health care systems worldwide, with disproportionate consequences for maternal and newborn health. Pregnant individuals and neonates faced both direct clinical consequences of severe acute respiratory syndrome–coronavirus-2 (SARS-CoV-2) infection and indirect effects of health system disruption. This narrative review synthesizes global evidence on the pandemic's impact on perinatal outcomes, neonatal care, breastfeeding practices, and financial burden on health care institutions, contrasting high-income countries (HICs) and low- and middle-income countries (LMICs). PubMed, the World Health Organization (WHO), the American Academy of Pediatrics (AAP), and the Centers for Disease Control and Prevention (CDC) databases were searched for peer-reviewed publications through early 2026. The pandemic increased maternal mortality, stillbirth, and neonatal morbidity, particularly in LMICs, alongside paradoxical preterm birth reductions in some HICs. Vertical SARS-CoV-2 transmission remained infrequent. Neonatal admissions fell while acuity and length of stay increased. Breastfeeding was profoundly disrupted by inconsistent separation policies and infection control measures. Health care institutions absorbed substantial additional costs from screening programs and care pathway reorganization. COVID-19 exposed and exacerbated existing global health inequities in maternal and neonatal care. Evidence-based, context-sensitive policies from the WHO, AAP, and CDC are essential to preserve perinatal care quality during future health emergencies.
- 20 July 2026
- Published by Georg Thieme Verlag KG in American Journal of Perinatology
COVID-19 and Global Perinatal Health: Lessons Learned on Maternal-Neonatal Outcomes, Infant Feeding Practices, and Health Care Economics across Income Settings
The coronavirus disease 2019 (COVID-19) pandemic fundamentally disrupted health care systems worldwide, with disproportionate consequences for maternal and newborn health. Pregnant individuals and neonates faced both direct clinical consequences of severe acute respiratory syndrome–coronavirus-2 (SARS-CoV-2) infection and indirect effects of health system disruption. This narrative review synthesizes global evidence on the pandemic's impact on perinatal outcomes, neonatal care, breastfeeding practices, and financial burden on health care institutions, contrasting high-income countries (HICs) and low- and middle-income countries (LMICs). PubMed, the World Health Organization (WHO), the American Academy of Pediatrics (AAP), and the Centers for Disease Control and Prevention (CDC) databases were searched for peer-reviewed publications through early 2026. The pandemic increased maternal mortality, stillbirth, and neonatal morbidity, particularly in LMICs, alongside paradoxical preterm birth reductions in some HICs. Vertical SARS-CoV-2 transmission remained infrequent. Neonatal admissions fell while acuity and length of stay increased. Breastfeeding was profoundly disrupted by inconsistent separation policies and infection control measures. Health care institutions absorbed substantial additional costs from screening programs and care pathway reorganization. COVID-19 exposed and exacerbated existing global health inequities in maternal and neonatal care. Evidence-based, context-sensitive policies from the WHO, AAP, and CDC are essential to preserve perinatal care quality during future health emergencies.
- 1 July 2026
- Published by Georg Thieme Verlag KG in American Journal of Perinatology
Regenerative Cell and Cell-Free Therapies for Necrotizing Enterocolitis: Progress Toward Clinical Translation
Necrotizing enterocolitis (NEC) remains one of the most devastating gastrointestinal diseases of prematurity, carrying high mortality and long-term morbidity with no targeted disease-modifying therapy currently available. This review synthesizes preclinical and translational evidence for stem cell- and extracellular vesicle (EV)-based regenerative therapies in NEC and identifies the critical steps required for clinical translation. A narrative review of preclinical studies, systematic reviews, meta-analyses, and early-phase clinical trial data evaluating stem cell-based and cell-free EV therapies for NEC was performed. Evidence was organized across cell populations, mesenchymal stem cells (MSCs), amniotic fluid stem cells (AFSCs), placental-derived stem cells, and neural stem cells, and their derived EVs and exosomes, with synthesis of mechanistic, translational, safety, and ethical considerations. Multiple stem cell types consistently reduce NEC incidence, severity, and mortality in experimental models. Protective effects are mediated through epithelial regeneration, barrier reinforcement, Wnt/β-catenin pathway activation, immunomodulation, and angiogenesis. Cell-free strategies using MSC- and AFSC-derived EVs reproduce comparable benefits with a more favorable manufacturing and safety profile. Early-phase clinical trials of MSCs in other neonatal conditions confirm short-term tolerability, though no NEC-specific stem cell or EV trial has been completed. Regenerative cell and cell-free therapies represent a compelling disease-modifying strategy for NEC. Advancing this field requires standardized cell and EV characterization, optimized dosing and delivery protocols, large-animal model validation, and rigorously designed early-phase clinical trials with careful attention to safety, ethics, and regulatory frameworks.
- 1 July 2026
- Published by Georg Thieme Verlag KG in American Journal of Perinatology
Regenerative Cell and Cell-Free Therapies for Necrotizing Enterocolitis: Progress Toward Clinical Translation
Necrotizing enterocolitis (NEC) remains one of the most devastating gastrointestinal diseases of prematurity, carrying high mortality and long-term morbidity with no targeted disease-modifying therapy currently available. This review synthesizes preclinical and translational evidence for stem cell- and extracellular vesicle (EV)-based regenerative therapies in NEC and identifies the critical steps required for clinical translation. A narrative review of preclinical studies, systematic reviews, meta-analyses, and early-phase clinical trial data evaluating stem cell-based and cell-free EV therapies for NEC was performed. Evidence was organized across cell populations, mesenchymal stem cells (MSCs), amniotic fluid stem cells (AFSCs), placental-derived stem cells, and neural stem cells, and their derived EVs and exosomes, with synthesis of mechanistic, translational, safety, and ethical considerations. Multiple stem cell types consistently reduce NEC incidence, severity, and mortality in experimental models. Protective effects are mediated through epithelial regeneration, barrier reinforcement, Wnt/β-catenin pathway activation, immunomodulation, and angiogenesis. Cell-free strategies using MSC- and AFSC-derived EVs reproduce comparable benefits with a more favorable manufacturing and safety profile. Early-phase clinical trials of MSCs in other neonatal conditions confirm short-term tolerability, though no NEC-specific stem cell or EV trial has been completed. Regenerative cell and cell-free therapies represent a compelling disease-modifying strategy for NEC. Advancing this field requires standardized cell and EV characterization, optimized dosing and delivery protocols, large-animal model validation, and rigorously designed early-phase clinical trials with careful attention to safety, ethics, and regulatory frameworks.
- Open Access
- 1 June 2026
- Published by Elmer Press, Inc. in International Journal of Clinical Pediatrics
- Vol. 15  (2) , 37-50
Wearable Devices in Pediatric Obesity: A Comprehensive Review of Current Applications and Future Directions
Pediatric obesity represents a critical global public health crisis affecting millions of children and adolescents worldwide. Traditional obesity interventions face significant challenges related to adherence, engagement, and long-term efficacy. Wearable devices have emerged as promising tools for monitoring physical activity, metabolic parameters, and supporting behavior change in youth with obesity. This targeted literature review examines the current scope, applications, and effectiveness of wearable devices in managing childhood and adolescent obesity. We conducted a targeted literature review using PubMed and Google Scholar databases to identify studies published between 2010 and 2025. Search terms included wearable devices, pediatric obesity, activity trackers, accelerometers, continuous glucose monitors (CGMs), smartwatches, children, and adolescents. We focused on randomized controlled trials, systematic reviews, meta-analyses, and observational studies evaluating wearable devices in pediatric populations with obesity or overweight. Wearable devices demonstrate significant potential across multiple domains in pediatric obesity management. Activity trackers and accelerometers show effectiveness in increasing physical activity and improving anthropometric outcomes including body mass index (BMI), BMI z-score, and body fat percentage. Consumer-grade devices like Fitbit and research-grade accelerometers have shown acceptable accuracy and feasibility in pediatric populations. CGMs are emerging as valuable tools for understanding glycemic variability and supporting dietary behavior change in youth with obesity. Heart rate monitors and smartwatches provide real-time biofeedback that enhances engagement. However, heterogeneity in device types, intervention duration, and outcome measures limits definitive conclusions. In conclusion, wearable devices represent a versatile and increasingly accessible approach to pediatric obesity management. While current evidence supports their use for physical activity promotion and metabolic monitoring, significant gaps remain regarding long-term adherence, optimal implementation strategies, and integration into clinical care pathways. Future research should focus on standardizing outcome measures, evaluating cost-effectiveness, and developing age-appropriate interventions that maximize the unique potential of wearable technology in combating the pediatric obesity epidemic.
- 1 June 2026
- Published by Elmer Press, Inc. in International Journal of Clinical Pediatrics
- Vol. 15  (2) , 37-50
Open AccessWearable Devices in Pediatric Obesity: A Comprehensive Review of Current Applications and Future Directions
Pediatric obesity represents a critical global public health crisis affecting millions of children and adolescents worldwide. Traditional obesity interventions face significant challenges related to adherence, engagement, and long-term efficacy. Wearable devices have emerged as promising tools for monitoring physical activity, metabolic parameters, and supporting behavior change in youth with obesity. This targeted literature review examines the current scope, applications, and effectiveness of wearable devices in managing childhood and adolescent obesity. We conducted a targeted literature review using PubMed and Google Scholar databases to identify studies published between 2010 and 2025. Search terms included wearable devices, pediatric obesity, activity trackers, accelerometers, continuous glucose monitors (CGMs), smartwatches, children, and adolescents. We focused on randomized controlled trials, systematic reviews, meta-analyses, and observational studies evaluating wearable devices in pediatric populations with obesity or overweight. Wearable devices demonstrate significant potential across multiple domains in pediatric obesity management. Activity trackers and accelerometers show effectiveness in increasing physical activity and improving anthropometric outcomes including body mass index (BMI), BMI z-score, and body fat percentage. Consumer-grade devices like Fitbit and research-grade accelerometers have shown acceptable accuracy and feasibility in pediatric populations. CGMs are emerging as valuable tools for understanding glycemic variability and supporting dietary behavior change in youth with obesity. Heart rate monitors and smartwatches provide real-time biofeedback that enhances engagement. However, heterogeneity in device types, intervention duration, and outcome measures limits definitive conclusions. In conclusion, wearable devices represent a versatile and increasingly accessible approach to pediatric obesity management. While current evidence supports their use for physical activity promotion and metabolic monitoring, significant gaps remain regarding long-term adherence, optimal implementation strategies, and integration into clinical care pathways. Future research should focus on standardizing outcome measures, evaluating cost-effectiveness, and developing age-appropriate interventions that maximize the unique potential of wearable technology in combating the pediatric obesity epidemic.
- Open Access
- 26 February 2026
- Published by Georg Thieme Verlag KG in American Journal of Perinatology
- Vol. 43  (13) , 1714-1722
NEC-Associated Bronchopulmonary Dysplasia and the Gut–Lung Axis in Preterm Infants
Prevailing evidence underscores the critical influence of infant gut microbiota on systemic immune responses and intestinal health. The role of functional programming of effector immune cells at extra-intestinal mucosal sites is increasing in interest. Common connections between development of gut and lung microbiomes and reciprocal signaling between the two organ systems has reinforced the concept of a “gut–lung axis.” Narrative review of existing literature evaluating mechanistic evidence linking microbial dysbiosis and necrotizing enterocolitis (NEC) to development of preterm acute lung injury and subsequent progression to chronic lung disease or bronchopulmonary dysplasia (BPD). Evidence across animal and human studies indicates that gut-derived microbial ligands and metabolites are foundational in programming respiratory immunity. Conversely, primary pulmonary insults appear to trigger reciprocal shifts in gut microbiome function. This bidirectional signaling likely drives the clinical association between NEC-associated systemic inflammation and the subsequent increased risk of BPD. By focusing on mediators involved in this gut–lung crosstalk, we seek to highlight avenues such as microbiome modulation or targeted anti-inflammatory signaling to prevent or reduce the severity of two of the major morbidities of prematurity.
- 26 February 2026
- Published by Georg Thieme Verlag KG in American Journal of Perinatology
- Vol. 43  (13) , 1714-1722
Open AccessNEC-Associated Bronchopulmonary Dysplasia and the Gut–Lung Axis in Preterm Infants
Prevailing evidence underscores the critical influence of infant gut microbiota on systemic immune responses and intestinal health. The role of functional programming of effector immune cells at extra-intestinal mucosal sites is increasing in interest. Common connections between development of gut and lung microbiomes and reciprocal signaling between the two organ systems has reinforced the concept of a “gut–lung axis.” Narrative review of existing literature evaluating mechanistic evidence linking microbial dysbiosis and necrotizing enterocolitis (NEC) to development of preterm acute lung injury and subsequent progression to chronic lung disease or bronchopulmonary dysplasia (BPD). Evidence across animal and human studies indicates that gut-derived microbial ligands and metabolites are foundational in programming respiratory immunity. Conversely, primary pulmonary insults appear to trigger reciprocal shifts in gut microbiome function. This bidirectional signaling likely drives the clinical association between NEC-associated systemic inflammation and the subsequent increased risk of BPD. By focusing on mediators involved in this gut–lung crosstalk, we seek to highlight avenues such as microbiome modulation or targeted anti-inflammatory signaling to prevent or reduce the severity of two of the major morbidities of prematurity.
- Open Access
- 21 February 2026
- Published by Medip Academy in International Journal of Contemporary Pediatrics
- Vol. 13  (3) , 505-511
Brucellosis presenting as prolonged fever of unknown origin in a two-year-old child: a diagnostic challenge
Brucellosis is a zoonotic disease with diverse clinical manifestations and is an uncommon but important cause of prolonged fever in children. Diagnosis may be delayed due to nonspecific symptoms, limited exposure history, and variable serologic findings. This report describes a two-year-old patient who experienced 17 days of recurrent fever associated with fatigue, myalgia, and diarrhea following a horse-related injury two months earlier. Extensive evaluation demonstrated elevated inflammatory markers, thrombocytosis, cervical lymphadenopathy, and hepatic lesions, but the etiology was unrevealing. A thorough exposure history prompted targeted zoonotic testing, which identified Brucella-positive IgM in the absence of detectable IgG, consistent with an acute Brucella infection in the appropriate clinical context. This case highlights the importance of detailed exposure history and consideration of brucellosis in the differential diagnosis of pediatric fever of unknown origin (FUO), even in the absence of classic presentation.
- 21 February 2026
- Published by Medip Academy in International Journal of Contemporary Pediatrics
- Vol. 13  (3) , 505-511
Open AccessBrucellosis presenting as prolonged fever of unknown origin in a two-year-old child: a diagnostic challenge
Brucellosis is a zoonotic disease with diverse clinical manifestations and is an uncommon but important cause of prolonged fever in children. Diagnosis may be delayed due to nonspecific symptoms, limited exposure history, and variable serologic findings. This report describes a two-year-old patient who experienced 17 days of recurrent fever associated with fatigue, myalgia, and diarrhea following a horse-related injury two months earlier. Extensive evaluation demonstrated elevated inflammatory markers, thrombocytosis, cervical lymphadenopathy, and hepatic lesions, but the etiology was unrevealing. A thorough exposure history prompted targeted zoonotic testing, which identified Brucella-positive IgM in the absence of detectable IgG, consistent with an acute Brucella infection in the appropriate clinical context. This case highlights the importance of detailed exposure history and consideration of brucellosis in the differential diagnosis of pediatric fever of unknown origin (FUO), even in the absence of classic presentation.
- 19 February 2026
- Published by Georg Thieme Verlag KG in American Journal of Perinatology
- Vol. 43  (13) , 1701-1713
A Pathophysiological Approach for Early Detection and Prevention of AKI in the NICU
This study aimed to summarize contemporary evidence on the definition, epidemiology, risk factors, and prevention of acute kidney injury (AKI) in critically ill and preterm infants in the neonatal intensive care unit (NICU), and to highlight prevention-focused strategies to improve outcomes. Narrative review of current literature evaluating AKI burden, diagnostic criteria, modifiable and nonmodifiable risk factors, and preventive interventions in neonatal intensive care settings. AKI is common in critically ill and preterm infants and is associated with increased mortality, prolonged hospitalization, neurodevelopmental impairment, and progression to chronic kidney disease. Modified Kidney Disease: Improving Global Outcomes criteria have improved diagnostic consistency and revealed particularly high AKI prevalence in extremely low birth weight infants. Key modifiable risk factors include hemodynamic instability, patent ductus arteriosus, nephrotoxic drug exposure, fluid overload, and sepsis, while preventive strategies span optimized antenatal management, therapeutic hypothermia for hypoxic ischemic encephalopathy, careful postnatal hemodynamic and fluid management, nephrotoxic drug stewardship, early infection control, individualized ductus arteriosus therapy, and potential use of caffeine, alongside emerging urinary biomarkers for earlier detection. Given limited therapeutic options once AKI occurs, prevention through structured surveillance, timely identification of high-risk states, and rigorous implementation of kidney protective practices is essential. Integrating quality improvement, protocolized care pathways, and educational outreach within NICUs offers the greatest promise for improving short and long-term outcomes in infants with AKI.
- 19 February 2026
- Published by Georg Thieme Verlag KG in American Journal of Perinatology
- Vol. 43  (13) , 1701-1713
A Pathophysiological Approach for Early Detection and Prevention of AKI in the NICU
This study aimed to summarize contemporary evidence on the definition, epidemiology, risk factors, and prevention of acute kidney injury (AKI) in critically ill and preterm infants in the neonatal intensive care unit (NICU), and to highlight prevention-focused strategies to improve outcomes. Narrative review of current literature evaluating AKI burden, diagnostic criteria, modifiable and nonmodifiable risk factors, and preventive interventions in neonatal intensive care settings. AKI is common in critically ill and preterm infants and is associated with increased mortality, prolonged hospitalization, neurodevelopmental impairment, and progression to chronic kidney disease. Modified Kidney Disease: Improving Global Outcomes criteria have improved diagnostic consistency and revealed particularly high AKI prevalence in extremely low birth weight infants. Key modifiable risk factors include hemodynamic instability, patent ductus arteriosus, nephrotoxic drug exposure, fluid overload, and sepsis, while preventive strategies span optimized antenatal management, therapeutic hypothermia for hypoxic ischemic encephalopathy, careful postnatal hemodynamic and fluid management, nephrotoxic drug stewardship, early infection control, individualized ductus arteriosus therapy, and potential use of caffeine, alongside emerging urinary biomarkers for earlier detection. Given limited therapeutic options once AKI occurs, prevention through structured surveillance, timely identification of high-risk states, and rigorous implementation of kidney protective practices is essential. Integrating quality improvement, protocolized care pathways, and educational outreach within NICUs offers the greatest promise for improving short and long-term outcomes in infants with AKI.
- 31 December 2025
- Published by Georg Thieme Verlag KG in American Journal of Perinatology
- Vol. 43  (10) , 1269-1280
Understanding the Impact of Patent Ductus Arteriosus and Treatment Strategies on Acute Kidney Injury in Preterm Infants
Acute kidney injury (AKI) is a clinically significant complication in preterm neonates, leading to increased morbidity, mortality, and risk of long-term kidney dysfunction. Within this vulnerable population, the presence of a hemodynamically significant patent ductus arteriosus (PDA) may further exacerbate AKI risk. The relationship between PDA and AKI is complex, involving both the pathophysiological consequences of altered hemodynamics (e.g., ductal steal) causing renal ischemia and the potential nephrotoxic effects of therapeutic interventions. However, the existing literature provided limited insight into the impact of PDA and its management on AKI in preterm infants, with most studies relying on retrospective designs. There is a notable absence of consensus regarding the comparative effects of conservative, pharmacologic, and surgical PDA management strategies on AKI outcomes. This study directly addresses these knowledge gaps by synthesizing findings from diverse clinical trials, cohort studies, and meta-analyses into a single, comprehensive resource, aiming to inform future research and guide best practices for managing PDA-related AKI in preterm neonates.
- 31 December 2025
- Published by Georg Thieme Verlag KG in American Journal of Perinatology
- Vol. 43  (10) , 1269-1280
Understanding the Impact of Patent Ductus Arteriosus and Treatment Strategies on Acute Kidney Injury in Preterm Infants
Acute kidney injury (AKI) is a clinically significant complication in preterm neonates, leading to increased morbidity, mortality, and risk of long-term kidney dysfunction. Within this vulnerable population, the presence of a hemodynamically significant patent ductus arteriosus (PDA) may further exacerbate AKI risk. The relationship between PDA and AKI is complex, involving both the pathophysiological consequences of altered hemodynamics (e.g., ductal steal) causing renal ischemia and the potential nephrotoxic effects of therapeutic interventions. However, the existing literature provided limited insight into the impact of PDA and its management on AKI in preterm infants, with most studies relying on retrospective designs. There is a notable absence of consensus regarding the comparative effects of conservative, pharmacologic, and surgical PDA management strategies on AKI outcomes. This study directly addresses these knowledge gaps by synthesizing findings from diverse clinical trials, cohort studies, and meta-analyses into a single, comprehensive resource, aiming to inform future research and guide best practices for managing PDA-related AKI in preterm neonates.